MAIA Biotechnology, Inc. filings document the regulatory record for a clinical-stage oncology company developing ateganosine for non-small cell lung cancer. Form 8-K reports cover THIO-101 clinical updates, oncology conference materials, shareholder communications on the development pipeline, FDA Fast Track disclosure, and forward-looking risk language tied to investigational drug development.
The company’s filings also document capital structure and governance matters, including an underwritten common stock offering conducted under an effective Form S-3 shelf registration, the related underwriting agreement and use-of-proceeds disclosure, executive compensation actions, and annual meeting proxy matters such as director elections and auditor ratification.
MAIA Biotechnology furnished a Regulation FD Form 8-K to share a press release titled “MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer.” The company states this information is being provided for disclosure purposes.
The Item 7.01 materials are deemed “furnished” rather than “filed,” so they are not subject to Section 18 of the Exchange Act and are not incorporated by reference into other filings. Exhibits include the press release and scientific posters for the THIO-101 and THIO-104 trials, along with the cover page interactive data file.
MAIA Biotechnology entered a Securities Purchase Agreement for a private placement of 603,769 shares of common stock at $1.22 per share, together with warrants to purchase up to 603,769 shares, for expected gross proceeds of approximately $736,600. The warrants are exercisable at $1.52, begin six months after issuance, and expire three years from the issuance date.
The securities are being issued as restricted under Rule 144 with no registration rights and are offered in reliance on Section 4(a)(2) and/or Rule 506. Closing is expected on October 15, 2025, subject to customary closing conditions. The company plans to use net proceeds to fund the starting cost for Step 1 of Part C of its Phase II THIO‑101 trial and for working capital.
MAIA Biotechnology filed a current report describing a new treasury strategy that adds digital assets to how it manages its corporate funds. The company announced a plan to hold a portion of its treasury in a diversified portfolio focused on top-tier cryptocurrency assets, as detailed in an accompanying press release.
This move formally introduces exposure to cryptocurrencies at the corporate level, in addition to traditional cash and financial assets. The filing emphasizes that statements about this strategy and its future impact are forward-looking and subject to risks and uncertainties, including broader business, regulatory, and market factors affecting the company’s operations and product development.
MAIA Biotechnology reported a director stock-option grant disclosed on a Form 4. Stan V. Smith, a company director, received an award of 24,844 stock options on 10/02/2025 under the 2021 Equity Incentive Plan. The options have an exercise price of $1.80, vest 100% on the grant date, are exercisable immediately, and expire on 10/02/2035. The filing shows these shares are beneficially owned indirectly through The Stan V. Smith Trust Dated 1993, and the Form 4 was signed on 10/06/2025. The disclosure provides a clear record of insider compensation and ownership change but does not include company-wide share counts or percent ownership to measure dilution impact.
MAIA Biotechnology director Theagene Jean-Manasse received a grant of stock options for 20,459 shares on 10/02/2025. The options have an exercise price of $1.8, vest 100% on the grant date, are exercisable immediately, and expire on 10/02/2035. The filing shows the transaction was reported on 10/06/2025 and was filed as a Form 4 by one reporting person. The grant was made under the 2021 Equity Incentive Plan and represents a direct beneficial ownership of 20,459 shares via options.
Cristian Luput, a director of MAIA Biotechnology, Inc. (MAIA), reported a grant of stock options on 10/02/2025. The grant consists of 21,434 options under the company's 2021 Equity Incentive Plan that vest 100% on the grant date and are immediately exercisable. The options have an exercise price of $1.8 per share and expire on 10/02/2035.
The Form 4 was signed on 10/06/2025 and indicates the filing was submitted by one reporting person. The disclosure shows direct beneficial ownership of 21,434 shares following the transaction. No cash proceeds, sales, or other derivative transactions are reported in this filing.
MAIA Biotechnology, Inc. director Louie Ngar Yee reported a grant of 25,331 stock options on 10/02/2025. The options have an exercise price of $1.80, vest 100% immediately on the grant date, are exercisable immediately, and expire on 10/02/2035. The Form 4 indicates the filing was completed on 10/06/2025 and the reporting person is filing individually as a director. The grant was made under the company’s 2021 Equity Incentive Plan and represents a direct beneficial ownership of 25,331 shares upon exercise.
MAIA Biotechnology, Inc. director Ramiro Guerrero was granted 20,459 stock options on 10/02/2025 under the 2021 Equity Incentive Plan. The options are exercisable immediately and vest 100% on the grant date, giving the holder the right to buy 20,459 shares of common stock. The reported conversion/exercise price is $1.80 per share and the options expire on 10/02/2035. Following this transaction, the reporting person beneficially owns 20,459 derivative shares as disclosed on the Form 4.
MAIA Biotechnology director Steven M. Chaouki received a grant of 20,946 stock options under the 2021 Equity Incentive Plan. The options are exercisable immediately, vesting 100% on grant, and carry an exercise price of $1.8 per share. The award represents a direct ownership interest of 20,946 shares underlying common stock following the transaction. The options expire ten years from grant and were reported on the required Form 4 filing.
This action increases the director's potential economic exposure to the company’s common stock and creates a near-term option position that could be exercised to acquire shares at the stated exercise price.
Stan V. Smith, a director of MAIA Biotechnology, Inc. (MAIA), purchased 19,230 shares of common stock on 10/01/2025 at a price of $1.30 per share under a Securities Purchase Agreement and the company’s 2021 Equity Incentive Plan. The transaction increased beneficial ownership to 1,324,289 shares, held indirectly through The Stan V. Smith Trust Dated 1993. In the same transaction Mr. Smith acquired 19,230 warrants (treated as options) with a $1.57 exercise price; those options become exercisable six months after issuance and expire three years after issuance (exercise window: 04/01/2026 through 10/01/2028). The Form 4 was signed on 10/02/2025.